ORGANIZATION
Cancel or Postpone FY2025 Revision, or Scrap Off-Year Scheme: New JPA Chief
The Japan Pharmaceutical Association (JPA) will be pushing for calling off or postponing the FY2025 drug price revision or abolishing the “off-year” scheme outright, the group’s new president Susumu Iwatsuki said on July 17. Iwatsuki made the comment at his…
To read the full story
Related Article
- Japan Pharmacy Group Demands Abolishing Off-Year Price Revisions
November 22, 2024
ORGANIZATION
- JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
April 15, 2026
- Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
- Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
- Generic Use Rate Hits 90% for First Time in October-December: JGA
April 7, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





